Safety and Efficacy Study of Bimosiamose Cream to Treat Psoriasis
- Registration Number
- NCT00823693
- Lead Sponsor
- Revotar Biopharmaceuticals AG
- Brief Summary
The purpose of this study is to determine whether Bimosiamose Cream is safe and effective in the treatment of plaque type psoriasis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 107
Inclusion Criteria
- Clinical diagnosis of plaque type psoriasis PASI score of 5-15
- At least 18 years of age
- Written informed consent
Exclusion Criteria
- Active skin infection
- More than 20% Body Surface Area (BSA) affected by psoriasis
- Use of certain anti-psoriasis medication or treatments
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Bimosiamose Cream Bimosiamose Cream - Placebo Cream Placebo Cream -
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does bimosiamose cream target in chronic plaque psoriasis?
How does bimosiamose cream compare to standard-of-care treatments like TNF-alpha inhibitors in phase 2 trials?
Are there specific biomarkers associated with response to bimosiamose 5% cream in psoriasis patients?
What adverse events are reported with bimosiamose cream and how are they managed in clinical trials?
What are the potential combination therapies involving bimosiamose for plaque psoriasis treatment?
Trial Locations
- Locations (1)
Charité Campus Mitte, Klinik für Dermatologie, Venerologie und Allergologie
🇩🇪Berlin, Germany
Charité Campus Mitte, Klinik für Dermatologie, Venerologie und Allergologie🇩🇪Berlin, Germany